Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVistaGen Therapeutics Inc

VistaGen Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1828 USD 0.02 ( 11.60%)
Last update at 2026-11-09T17:58:00Z
VOLUME
610612
Market Cap
71.00M

Momentum Score

…

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.17
Low
0.18
High
52 Week Price Range
1.90
Low
4.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders; its lead program AV-101 is an oral prodrug modulating NMDA receptor pathways for depressive disorders. Long-term growth may be driven by positive clinical data, regulatory approvals and licensing or commercialization deals, which could make it attractive to investors seeking exposure to novel CNS therapies.

Material risks include clinical or regulatory failure for a single-lead development-stage company, no product revenue requiring dilutive financing, and scientific and competitive uncertainty in CNS drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
-
Revenue TTM
0.70M
Revenue Per Share
0.02
Gross Profit TTM
0.70M
Debt / Equity
0.02
ROE
-46.28%
Net Debt
-117.05M
ROCE
-50.45%
Diluted EPS TTM
-1.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -59.24M -47.76M -17.93M -20.77M -24.59M
Net income -59.25M -47.76M -17.93M -20.77M -24.59M
Selling general administrative 14.66M 10.45M 6.55M 6.60M 7.43M
Selling and marketing expenses 1.90M 2.80M - - -
Gross profit -0.23M 1.11M 1.09M - -
Reconciled depreciation 0.53M 0.71M 0.12M 0.10M 0.09M
Ebit -59.80M -47.78M -17.93M -20.80M -24.53M
Ebitda -59.27M -46.82M -17.80M -20.65M -24.44M
Depreciation and amortization 0.53M 0.96M 0.13M 0.15M 0.09M
Non operating income net other - - - - -0.02M
Operating income -59.27M -47.78M -17.93M -20.80M -24.56M
Other operating expenses 59.04M 48.66M 19.02M 19.97M 24.53M
Interest expense 0.02M 0.23M 0.01M 0.01M 8.00M
Tax provision 0.01M 0.00M 0.00M 0.00M 0.00M
Interest income 0.03M 0.02M 0.01M 0.04M 0.01M
Net interest income 0.03M 0.02M 0.00M 0.03M -0.01M
Income tax expense 0.01M 0.00M 0.00M 0.00M 0.00M
Total revenue -0.23M 1.11M 1.09M 0.00M 0.00M
Total operating expenses 59.04M 48.66M 19.02M 19.97M 24.53M
Total other income expense net 0.03M 0.02M 0.00M 0.03M -0.05M
Net income from continuing ops -59.25M -47.76M -17.93M -20.77M -24.59M
Net income applicable to common shares -59.25M -48.71M -42.32M -22.04M -25.73M
Preferred stock and other adjustments - 0.95M - - -
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 123.65M 21.09M 74.64M 108.28M 5.77M
Other current assets 0.07M 0.80M 0.07M 0.03M 0.00M
Total liab 9.37M 9.01M 9.93M 16.30M 11.50M
Total stockholder equity 114.29M 12.08M 64.72M 91.98M -5.73M
Deferred long term liab - 0.71M 0.47M 0.53M 0.36M
Other current liab 2.23M 0.79M 1.33M 1.56M 0.56M
Common stock 0.03M 0.01M 0.21M 0.18M 0.05M
Capital stock 0.03M 0.01M 0.21M 0.19M 0.05M
Retained earnings -356.21M -326.85M -267.60M -219.84M -201.91M
Other liab - 2.31M 1.56M 2.49M -
Other assets - 0.81M 0.57M 0.58M 0.40M
Cash 119.17M 16.64M 68.14M 103.11M 1.36M
Total current liabilities 5.12M 4.57M 5.77M 4.19M 2.77M
Current deferred revenue 0.79M 0.71M 1.24M 1.42M -
Net debt -117.05M -13.92M -65.10M -99.39M 2.74M
Short term debt 0.55M 0.59M 0.43M 0.37M 0.37M
Short long term debt - 0.11M - - 0.06M
Short long term debt total 2.12M 2.72M 3.04M 3.72M 4.09M
Other stockholder equity 470.47M 338.92M 332.11M 311.63M 196.12M
Property plant equipment - 2.77M 0.41M 3.59M 3.79M
Total current assets 120.67M 17.51M 71.00M 104.12M 1.58M
Net tangible assets - 12.08M 64.72M 91.97M -5.73M
Net receivables - 0.80M 0.34M 0.04M -
Inventory - -0.74M 2.45M 0.94M -
Accounts payable 1.55M 2.47M 2.76M 0.84M 1.84M
Accumulated other comprehensive income 0.00M - - - -1.04M
Common stock total equity - - 0.21M 0.18M 0.05M
Preferred stock total equity - - - 0.03M 0.00M
Retained earnings total equity - - -267.60M -219.84M -201.91M
Treasury stock - - -3.97M -3.97M -3.97M
Non currrent assets other 0.73M 0.81M 0.57M 0.58M 0.40M
Deferred long term asset charges - - - 0.23M -
Non current assets total 2.98M 3.58M 3.65M 4.16M 4.19M
Capital lease obligations 2.12M 2.61M 3.04M 3.72M 4.04M
Long term debt total - - - - 0.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.74M -0.20M -0.28M 0.00M -0.17M
Change to liabilities 0.00M 1.69M 3.72M -0.39M 1.34M
Total cashflows from investing activities - -0.20M -0.28M -0.28M -0.17M
Net borrowings - -0.00M -0.38M -0.30M -0.22M
Total cash from financing activities -1.04M 10.48M 114.10M 4.01M 17.42M
Change to operating activities - -2.60M -0.24M 0.25M 0.68M
Net income -59.25M -47.76M -17.93M -20.77M -24.59M
Change in cash -51.50M -34.97M 101.75M -11.75M 2.72M
Begin period cash flow 68.14M 103.11M 1.36M 13.10M 10.38M
End period cash flow 16.64M 68.14M 103.11M 1.36M 13.10M
Total cash from operating activities -49.72M -45.26M -12.07M -15.76M -14.53M
Issuance of capital stock 0.10M 4.28M 109.47M 3.60M 17.04M
Depreciation 0.53M 0.71M 0.12M 0.10M 0.09M
Dividends paid -866.96M -945.10M -1385.60M -1263.60M 1139.90M
Change to inventory - - -51.00M 390.70M -20.77M
Change to account receivables - - -0.04M 0.30M -0.30M
Sale purchase of stock -0.17M 945.10M 1385.60M 1263.60M 1139.90M
Other cashflows from financing activities 867.03M 6.21M 5.23M 0.71M 0.61M
Change to netincome - 3.48M 2.31M 3.82M 3.59M
Capital expenditures 0.21M 0.20M 0.28M 0.28M 0.17M
Change receivables - - -0.04M 0.30M -0.30M
Cash flows other operating - -2.66M -0.24M 1.18M 5.35M
Cash and cash equivalents changes - -34.97M 101.75M -11.75M 2.72M
Change in working capital 2.03M -1.92M 3.44M 0.16M 1.72M
Stock based compensation 3.34M 3.48M 2.31M 3.82M 3.44M
Other non cash items -929.16M 0.23M -97.68M 0.11M 4.66M
Free cash flow -49.93M -45.46M -12.35M -15.76M -14.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VTGN
VistaGen Therapeutics Inc		 0.02
11.60%		 0.18 - - 101.72 0.88 8.05 -0.19
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

VistaGen Therapeutics Inc

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

343 Allerton Avenue, South San Francisco, CA, United States, 94080

650 577 3600

https://www.vistagen.com

48

Name Title Year Born
Mr. Shawn K. Singh J.D. CEO & Director 1963
Mr. Jerrold D. Dotson CPA, CPA Chief Financial Officer 1953
Mr. Reid G. Adler Esq., J.D. Chief Corp. Devel. & Legal Officer 1954
Mr. Joshua Prince M.B.A. Sr. VP of Bus. Operations NA
Mr. Mark Flather VP of Investor Relations NA
Ms. Jessica R. Haskell J.D. VP, Assoc. Gen. Counsel & Corp. Sec. NA
Ms. Trisha Fitzmaurice VP of HR NA
Dr. Allen Easley Cato III, M.D., Ph.D. Sr. VP of Devel. Operations NA
Dr. Mark J. Ginski Ph.D. Sr. VP and Head of Chemistry, Manufacturing & Controls 1972
Dr. Jaakko Lappalainen M.D., Ph.D. Sr. VP of Global Clinical Devel. & Pharmacovigilance NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…